Compare · BBLG vs EW
BBLG vs EW
Side-by-side comparison of Bone Biologics Corp (BBLG) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 47536.6x BBLG ($1.1M).
- Over the past year, BBLG is down 82.0% and EW is up 15.0% - EW leads by 97.0 points.
- BBLG has been more active in the news (6 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $1.1M
- $50.78B
- 1M return
- -11.09%
- -1.84%
- 1Y return
- -81.96%
- +15.02%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 5
- Recent ratings
- 0
- 25
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest BBLG
- SEC Form 25-NSE filed by Bone Biologics Corp
- SEC Form 4 filed by Director Gagnon Robert E.
- SEC Form 4 filed by Director Angle Siddhesh Rajendra
- SEC Form 4 filed by Director Meikle Phillip Terry Ii
- SEC Form 4 filed by Director Stroever Bruce
- SEC Form 8-K filed by Bone Biologics Corp
- SEC Form 8-K filed by Bone Biologics Corp
- Bone Biologics Expands Trial Sites
- Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form DEF 14A filed by Bone Biologics Corp
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision